Climate protection - Interpharma

A strong economic framework

Climate protection

The pharmaceutical companies in Switzerland play an active role in implementing the UN’s Sustainable Development Goals and improving health worldwide.

Overview Biodiversity Climate protection

The United Nations Environment Programme (UNEP) published a report in November 2019 calling for global emissions of greenhouse gases to be reduced by 7.6 percent annually between 2020 and 2030. Otherwise, the goal set in the 2015 Paris Agreement of limiting global warming to 1.5 degrees cannot be achieved. Despite the urgent need for action to counter climate change, the Madrid climate conference in December 2019 produced only a minimum compromise with vague wording and postponement of critical issues.

Under the umbrella of the European Health Union, the European Green Deal presented by the EU Commission at the end of 2019 envisages leading Europe to climate neutrality by 2050. With the establishment of a circular economy and research and innovation, industry plays a central role in this project.

Switzerland is playing a pioneering role in the implementation of the international climate goals. The country’s 2050 climate target envisages Switzerland achieving climate neutrality (known as net zero emissions) within the next 30 years. This means that no more greenhouse gases will be emitted than can be absorbed by natural and technical reservoirs.

Pharmaceutical industry activities

The pharmaceutical industry is committed to making a positive impact on patients’ lives. At the same time, it wants to operate sustainably, contribute to a healthy environment and take a leadership role in mitigating climate change.

The research-based pharmaceutical companies in Switzerland are actively involved at the interface of health, well-being and climate protection. Manufacturing processes and business activities in the pharmaceutical industry generate CO2 and other greenhouse gases, and the Interpharma members have therefore set themselves the goal of actively minimising their emissions and reducing their impact on the environment. Here, a large number of technologies and activities will be employed, among them the sustainable design of production processes, the integration of sustainability principles into supply chains, and increased self-regulation and monitoring.

In the course of these efforts, the pharmaceutical companies will increasingly enter into private-public partnerships and leverage synergies in order to achieve global and sustainable health. At a local level, too, efforts to protect the climate will be intensified. For example, many pharmaceutical locations in Switzerland now obtain energy from sustainable sources and use solar energy, thus making a significant contribution to the reduction of CO2 emissions.

Further information

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2023

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more